share_log

EyePoint Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Adage Capital Management, L.P.(9.90%),Robert Atchinson(9.90%), etc.

EyePoint Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Adage Capital Management, L.P.(9.90%),Robert Atchinson(9.90%), etc.

EyePoint Pharmaceuticals | SC 13G/A：超過5%持股股東披露文件(修正)-Adage Capital Management, L.P.(9.90%),Robert Atchinson(9.90%)等
美股SEC公告 ·  05/02 05:12
牛牛AI助理已提取核心訊息
EyePoint Pharmaceuticals, Inc. has been the subject of a Schedule 13G/A filing with the Securities and Exchange Commission, indicating a change in ownership by certain significant investors. The filing, dated April 30, 2024, was submitted by Adage Capital Management, L.P., along with individuals Robert Atchinson and Phillip Gross, who collectively reported shared voting and dispositive power over 5,156,299 shares of EyePoint Pharmaceuticals' common stock. This stake represents 9.90% of the company's class of securities. The filing amends and replaces the previous Schedule 13G filed on the same date in 2023. The shares are reported to be held in the ordinary course of business, with no intention of changing or influencing the control of the issuer. The principal business office for the reporting persons is located at 200 Clarendon Street, 52nd Floor, Boston, Massachusetts.
EyePoint Pharmaceuticals, Inc. has been the subject of a Schedule 13G/A filing with the Securities and Exchange Commission, indicating a change in ownership by certain significant investors. The filing, dated April 30, 2024, was submitted by Adage Capital Management, L.P., along with individuals Robert Atchinson and Phillip Gross, who collectively reported shared voting and dispositive power over 5,156,299 shares of EyePoint Pharmaceuticals' common stock. This stake represents 9.90% of the company's class of securities. The filing amends and replaces the previous Schedule 13G filed on the same date in 2023. The shares are reported to be held in the ordinary course of business, with no intention of changing or influencing the control of the issuer. The principal business office for the reporting persons is located at 200 Clarendon Street, 52nd Floor, Boston, Massachusetts.
EyePoint Pharmicals, Inc.一直是向美國證券交易委員會提交的附表13G/A文件的主體，這表明某些重要投資者的所有權發生了變化。該文件日期爲2024年4月30日，由Adage Capital Management, L.P. 以及個人羅伯特·阿欽森和菲利普·格羅斯提交，他們共同報告了對5,156,299股EyePoint Pharmaceuticals普通股的共同投票權和處置權。該股份佔公司證券類別的9.90％。該文件修訂並取代了先前於2023年同日提交的附表13G。據報道，這些股票是在正常業務過程中持有的，無意改變或影響發行人的控制權。申報人的主要業務辦公室位於馬薩諸塞州波士頓克拉倫登街200號52樓。
EyePoint Pharmicals, Inc.一直是向美國證券交易委員會提交的附表13G/A文件的主體，這表明某些重要投資者的所有權發生了變化。該文件日期爲2024年4月30日，由Adage Capital Management, L.P. 以及個人羅伯特·阿欽森和菲利普·格羅斯提交，他們共同報告了對5,156,299股EyePoint Pharmaceuticals普通股的共同投票權和處置權。該股份佔公司證券類別的9.90％。該文件修訂並取代了先前於2023年同日提交的附表13G。據報道，這些股票是在正常業務過程中持有的，無意改變或影響發行人的控制權。申報人的主要業務辦公室位於馬薩諸塞州波士頓克拉倫登街200號52樓。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。